Adagrasib versus docetaxel in KRAS
Summary
In the multicenter, phase 3 KRYSTAL-12 trial, adagrasib significantly prolonged progression-free survival versus docetaxel in previously treated patients with KRAS-mutant NSCLC, with a hazard ratio of 0.58 and comparable rates of grade ≥3 treatment-related adverse events. Median PFS was 5.5 months with adagrasib versus 3.8 months with docetaxel.
Key Findings
- Median PFS: 5.5 months (adagrasib) vs 3.8 months (docetaxel); HR 0.58; p<0.0001.
- Grade ≥3 treatment-related adverse events: 47% (adagrasib) vs 46% (docetaxel).
- Treatment-related deaths: 1% in both arms (4 vs 1 patients, respectively).
Clinical Implications
Adagrasib may become a preferred standard option over docetaxel for previously treated KRAS-mutant NSCLC, pending overall survival and quality-of-life data and access considerations.
Why It Matters
This is a definitive phase 3 head-to-head comparison establishing a targeted therapy advantage over chemotherapy in KRAS-mutant NSCLC, a historically difficult-to-treat subset.
Limitations
- Open-label design may introduce bias in assessment of secondary outcomes
- Overall survival and long-term safety data not reported in the abstract
Future Directions
Assess overall survival, patient-reported outcomes, resistance mechanisms, and optimal sequencing with other targeted agents and immunotherapies.
Study Information
- Study Type
- RCT
- Research Domain
- Treatment
- Evidence Level
- I - High-quality randomized, multicenter phase 3 trial with significant primary endpoint
- Study Design
- OTHER